Abstract
Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) or truncated S protein. Following mice vaccination, we measured T-cell response and antigen-specific neutralizing antibody (NAb) titer. All four candidates induced humoral immune responses, including elevated levels of total IgG and NAbs, and cell-mediated immune responses, including multiple cytokine expression. However, the full-length S DNA vaccine enhanced the immune responses most significantly. We then evaluated its appropriate antigen dose and vaccination schedule. Although all immunized groups showed higher immune response than the control group, inoculation with 50 μg antigen led to the highest NAb titer. Immunity was significantly increased after the third inoculation. Thus, the full-length S DNA vaccine can potentially prevent SARS-CoV-2 infection.
Keywords: DNA vaccine; SARS-CoV-2; Spike protein.
【저자키워드】 SARS-CoV-2, spike protein., DNA vaccine, 【초록키워드】 neutralizing antibody, public health, IgG, Coronavirus disease 2019, Vaccine, coronavirus, immune response, vaccination, S protein, spike, SARS-COV-2 infection, T-cell Response, Antigen, Protein, DNA, mice, group, humoral immune responses, dose, acute respiratory syndrome, control group, NAbs, candidate, Cell-mediated immune responses, full-length, full-length S, vaccination schedule, cytokine expression, Prevent, NAb titer, immunized, significantly increased, highest, caused, significantly, evaluated, elevated, 【제목키워드】 immunogenicity, the spike protein,